Understanding the complex nature of BP regulation accelerated after William Harvey description of the circulatory system in the 17th century, with each incremental advance reinforcing its multifactorial basis, and highlighted by Guyton iconic computer model of circulatory (BP) control in 1972 which incorporated empirically tested concepts of blood flow autoregulation and the pressure-natriuresis relationship.
B lood pressure (BP) level is determined by just 2 variables: peripheral vascular resistance and cardiac output, but it exhibits a Gaussian distribution in the general population indicating that it is the net effect of a multitude of independent factors each with a small cumulative effect (this can be extended to hypertension which is a dichotomization of the quantitative BP trait.). Individuals with BP at the higher end of the BP distribution have been noted to have a higher risk of stroke and cardiovascular disease as early as 2600 BC. 1 and cardiac output) rather than from the dissection of the complex genetic and physiological pathways involved. The major classes of antihypertensive drugs in current use act either as vasodilators or diuretics, which reduce peripheral vascular resistance and cardiac output, respectively. But the complexity of BP regulation means that current antihypertensive drugs, which all have a single site of action or target, can result in unpredictable and wide-ranging BP responses in individuals. The holy grail of hypertension research is neutralization of the excess cardiovascular risk posed by high BP. Among the scientific tools used to realize this goal is genomic research, based on the principle that identifying genes and genetic variants that influence the regulatory or counter-regulatory pathways of BP control will lead to the development of novel drugs and targeted treatment that will reduce high BP effectively without any adverse effects.
Crucially, genomic research requires an understanding of the magnitude of the genetic contribution to the BP phenotype because this has implications on the experimental strategies that need to be deployed. The Platt-Pickering debate in the 1950s focused on the observed Gaussian distribution of BP, or rather the lack of a bimodal distribution, to support a polygenic basis for the BP trait. 4, 5 Evidence from family studies show BP to be moderately heritable with 15% to 40% of clinic systolic BP, 15% to 30% of clinic diastolic BP, 69% and 51%, respectively, of ambulatory night-time systolic and diastolic BP, and 50% to 60% of long-term systolic or diastolic BP explained by variation in genetic factors. [6] [7] [8] [9] [10] The consensus view from these findings was that BP showed a complex non-Mendelian mode of inheritance with no single gene exerting a predominant effect on the trait, supporting the Pickering argument. However, since the 1930s, a growing list of rare syndromes of high and low BP has been identified presenting early in life, demonstrating a clear Mendelian inheritance and subsequently linked to rare mutations in genes, 5, 11 indicating the Platt argument. It is now evident that hypertension exists as a polygenic trait with the rare syndromes representing the extreme end of the BP distribution. More importantly, the discovery of genes responsible for the monogenic syndromes has highlighted the primacy of the kidneys and the adrenal glands in BP regulation and provided a valuable molecular layer to the expanding BP regulatory model. Indeed updating the 1960 Paige model to 2014 emphasizes the enormous contribution made by genetics in our understanding of BP regulation ( Figure 1 ). It is instructive to note from Figure 1B the disproportionate contribution of monogenic studies in contrast to genome-wide association studies (GWAS) in BP gene discoveries. Although the latter has been successful in discovering numerous single nucleotide polymorphisms for BP and hypertension, connecting these single nucleotide polymorphisms (SNPs) to causal pathways has been challenging.
From an epidemiological perspective, a majority of individuals with hypertension have essential or primary hypertension, which is thought to result from a genetic predisposition underlying the cumulative effects of various lifestyle factors over many years with no single underlying cause identified for the high BP. Secondary hypertension includes the monogenic forms of hypertension and other diseases that lead to hypertension, such as chronic kidney disease and renal artery stenosis. Among the monogenic causes of hypertension, it is estimated that 10% of all hypertension, possibly 20% to 25% of resistant hypertension, have primary aldosteronism 12 ; pheochromocytoma is present in 0.1% to 1% of patients with hypertension 13, 14 ; significant renal artery stenosis is found in ≈16% of hypertensive patients undergoing cardiac catheterization 15 ; and ≤42% of hypertensive patients have some evidence of chronic kidney disease. 16 The high prevalence of hypertension (≈27% of the adult population) and the high attributable cardiovascular risk (hypertension is primarily responsible for one quarter of the 52.8 million deaths recorded globally in 2010) 17 presents a clear justification for genomic studies, where unraveling the genetic architecture of the trait can lead to new treatments and new disease models resulting in a major beneficial impact on public health. The human genome project in 2001 toppled the first barrier to large-scale genomic studies in populations. Indeed in 2003, Francis Collins, who led the human genome project to completion predicted that by 2013 "predictive genetic tests will exist for many common conditions" and "each of us can learn of our individual risks for future illness." In 2014, although it seems that this prediction was a little too optimistic, in reality during the past 10 years, we have accrued a vast knowledge of the genetic architecture of wide range of human traits and diseases that would have been impossible without the human genome project. The bottleneck is in translating these discoveries into clinically useful applications for public health benefit. The aim of this review is to provide a global overview of the BP mechanisms that have been discovered through genetic studies and the challenges and opportunities for the near future.
The current list of known variants contributing to the genetic architecture of BP and hypertension includes >25 rare mutations and 53 SNPs (Table) . The genetic dissection of BP and hypertension started with studies of Mendelian BP syndromes initially using linkage analysis and more recently exome sequencing resulting in the discovery of causal mutations in genes primarily related to sodium homeostasis through renal and adrenal mechanisms. 5, 11 Elucidating the polygenic basis of BP and hypertension, however, remained unattainable until the advent of SNP-chip arrays that permitted interrogation of a large number of genetic variants cost-effectively and a reassessment of study design methods and adoption of rigorous criteria for establishing true-positive signals. This resulted in a series of GWAS for BP and hypertension identifying bonafide associations with single nucleotide polymorphisms. [18] [19] [20] [21] [22] [23] [24] [25] [26] The incremental discoveries of SNPs associated with BP with increasing sample sizes of GWAS have been summarized in several recent detailed reviews. 5, 27, 28 The updated Paige model in Figure 1B highlights the key issue with GWAS, which is the difficulty in relating the associated SNPs to causal genes. It is evident that the majority of BP-related GWAS SNPs are noncoding and identifying causal variants and the mechanisms through which they act present significant challenges. Although majority of GWAS studied BP as a quantitative trait, only 2 studies analyzed hypertension as a dichotomous trait, 22, 29 both of which resulted in identification of tractable signals in novel or established pathways of BP regulation. 22, [29] [30] [31] [32] One variant (rs13333226) 22 is located in the promoter region of Uromodulin gene (UMOD), which is exclusively expressed in the kidney and possibly affects BP through a novel sodium homeostatic pathway, whereas second promoter SNP lies near the endothelial nitric oxide synthase (eNOS) gene, which is known to mediate vascular tone. 29, 31 Among all the SNPs identified for quantitative BP, only 1 SNP (rs5068) has been reliably linked to a specific pathway (natriuretic peptide [NPPA/B]), whereas most of the remaining SNPs await robust elucidation of their causal genes and pathways (Table) .
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Monogenic Syndromes and Low-Frequency Variants
The monogenic forms of hypertension commonly feature volume expansion and low plasma renin activity secondary to salt retention. 11 The causative genetic mutations responsible for several monogenic forms of human hypertension have been discovered through positional cloning using large kindreds with multiple affected family members showing a clear inheritance pattern. Linkage analysis performed by genotyping highly polymorphic microsatellite markers, usually evenly spaced at 10 centimorgan (cM) intervals, has been successful at identifying specific regions of the chromosome that is linked to a monogenic trait. Usually this is followed by further fine-mapping of the region to identify the causative gene. Most of the monogenic forms of hypertension are because of gain-of-function mutations, and a majority of them alter gene function leading to increased mineralocorticoid activity or production, which accounts for the commonly observed clinical phenotype of volume expansion and suppressed plasma renin activity. 5 The monogenic hypertension syndromes are the classical examples where knowledge of the genetic mutation and the underlying perturbed pathway can inform targeted therapy-the molecular and clinical details of the classic monogenic BP syndromes are described below and are summarized in the Table.
Mineralocorticoid Pathway
Mineralocorticoid hormones (of which aldosterone accounts for 90%) produced by the adrenal cortex have a major role in homeostasis of blood volume and pressure by promoting renal sodium, chloride, and water reabsorption. In monogenic hypertensive disorders, single gene mutations lead to either a primary increase in the rate of sodium and chloride reabsorption in the distal nephron or enhancement of the effects of hormones with mineralocorticoid activity and consequently low plasma renin activity. In these disorders, the elevation of BP is more likely to be salt sensitive.
Glucocorticoid-Remediable Aldosteronism or Familial Hyperaldosteronism Type 1 (OMIM 103900) is an autosomal dominant syndrome in which hypertension is caused by increased aldosterone secretion driven by adrenocorticotropic hormone (ACTH). It results from a chimeric gene containing the 5′ regulatory sequences of 11β-hydroxylase (CYP11B1; which confers ACTH responsiveness) fused with the distal coding sequences of aldosterone synthase (CYP11B2) leading to ACTH rather than angiotensin II or potassium as the main controller of aldosterone secretion. 40 The specific treatment for hypertension in these individuals is low-dose glucocorticoids to suppress ACTH secretion, or amiloride, which directly blocks the epithelial sodium channel (ENaC), or spironolactone, which blocks binding of aldosterone to the mineralocorticoid receptor (MCR).
In contrast, Familial Hyperaldosteronism Type 2 (FH-II; OMIM 605635) is an autosomal dominant syndrome caused by hyperplasia or adenoma of the aldosterone-producing adrenal (APA) cortex. The genetic abnormality causing FH-II has been localized to chromosome 7p22 41 Apparent Mineralocorticoid Excess (OMIM 218030) is an another low-renin hypertension syndrome accompanied by hypokalemia and metabolic alkalosis. The main defect in AME is absence or reduced activity of 11β-hydroxysteroid dehydrogenase (HSD11B2), resulting in hypertension in which cortisol acts as if it were a potent mineralocorticoid. 42 Normally, both cortisol and aldosterone have MCR agonist activity, and HSD11B2 is protective by metabolizing cortisol to prevent its binding to the MCR. Acquired deficiency of this enzyme may result from its inhibition by glycyrrhizic acid (the active metabolite from licorice, certain brands of chewing tobacco, and carbenoloxone). Patients diagnosed with AME syndrome respond well to low sodium diet and spironolactone, which blocks binding of both cortisol and aldosterone to the MCR. Licorice-induced hypertension and hypokalemia are cortisol dependent and are corrected by the administration of spironolactone.
Another syndrome leading to severe early onset hypertension and hypertension during pregnancy is caused by a gain of function serine-to-leucine mutation in the MCR (S810L). One possible mechanism is that this mutation causes the receptor to be constitutively active and alters its specificity such that the steroid hormones, which lack a 21-hydroxyl group and are normally antagonistic (including progesterone and cortisone), act as agonists. 43, 44 Women with these mutations exhibit severe hypertension during pregnancy, exacerbated by the 100-fold rise in progesterone. Delivery of the fetus ameliorates the hypertension in pregnant women. Although no specific treatment strategy has been developed for men or nonpregnant women with this mutation, there is evidence that spironolactone can aggravate hypertension. 43, 44 Pseudohypoaldosteronism type II (Gordon's syndrome; OMIM 145260), an autosomal dominant form of hypertension associated with hyperkalemia, nonanion gap metabolic acidosis, and increased salt reabsorption by the kidney. Treatment consists of either a low-salt diet or thiazide diuretics, aimed at decreasing chloride intake and blocking Na + -Cl -cotransporter activity, respectively. Candidate genomic regions for genes involved in pseudohypoaldosteronism II were first identified by Mansfield et al in 1997, 45 and subsequently narrowed to the WNK lysine-deficient protein kinases by Wilson et al in 2001. 46 The WNK (with no lysine [K]) kinases play central roles in regulating mammalian BP by initiating a signaling pathway that controls the activity of critical ion cotransporters in the kidney NCC (Na + /Cl − ion cotransporter) and NKCC2 (Na + /K + /2Cl − cotransporter 2). 47, 48 There are 4 widely expressed mammalian WNK isoforms (WNK1, WNK2, WNK3, and WNK4) that exert their physiological effects by activating 2 highly related protein kinases termed SPS1-related proline/ alanine-rich kinase (also known as serine threonine kinase 39 [STK39]) and oxidative stress-responsive kinase 1. 46 Once activated, SPS1-related proline/alanine-rich kinase or oxidative stress-responsive kinase promote salt retention by phosphorylating and activating sodium ion cotransporters (NKCC1, NKCC2, and NCC) [49] [50] [51] [52] and inhibiting KCCs (potassium ion cotransporters).
53 WNK1 and WNK4 encode proteins involved in electrolyte homeostasis, and mutations within these genes result in reduced potassium excretion from the kidney, despite normal renal glomerular filtration. Intronic mutations within the human WNK1 gene have been shown to be associated with pseudohypoaldosteronism II with increased WNK1 mRNA expression. Mutations within a noncatalytic highly acidic motif of WNK4 located C terminal to the kinase domain (residues 557-567) also cause pseudohypoaldosteronism II. 46, 47 These mutations however, only account for a small fraction of families with pseudohypoaldosteronism II, leaving a large proportion of cases where the genetic basis of disease is unknown. A landmark study by Boyden et al 49 using exome sequencing, identified a further 2 genes, Kelch-like 3 (KLHL3) and Cullin 3 (CUL3), responsible for pseudohypoaldosteronism II. They showed that both dominant and recessive mutations within KLHL3 cause pseudohypoaldosteronism II, contrasting with mutations in WNK kinases and CUL3, which follow a dominant transmission pattern. 49 An independent study by Louis-Dit-Picard et al 54 also used whole exome sequencing combined with linkage analysis to identify KLHL3 mutations in 2 families with PHA II. These mutations are correlated with an increased activity of the NaCl cotransporter (NCC) in the distal convoluted tube. Again, these mutations were either dominant or recessive, with recessive cases having an earlier age of onset, and a more severe phenotype, than individuals with dominant mutations. CUL3 acts as a scaffolding protein that, through its N terminus, binds to the Bric-a-brac, Tramtrack, and Broad complex domain in KLHL3. KLHL3 is the substrate-recognition subunit of the ubiquitin ligase complex, recruiting substrates for ubiquitylation via its associated Kelch domain. The CUL3 C terminus also interacts with the RING-finger protein RBX1 (ring-box 1), which binds to ubiquitin-charged E2 enzymes and promotes transfer of ubiquitin on to the bound substrate. In addition to KLHL3, CUL3 can form distinct E3 ligase complexes with other Bric-a-brac, Tramtrack, and Broad domain-containing proteins. Because E3 ligases can regulate the endocytosis of integral membrane proteins, KLHL3 may regulate electrolyte homeostasis by regulating NCC trafficking via CRL3 KLHL3 -dependent ubiquitination. 51 Thus, CUL3 and KLHL3 mutations putatively inhibit the ubiquitylation of WNK4, and probably other WNK isoforms, by the CRL3 KLHL3 complex, and result in the cellular accumulation of these master regulators of BP. This, in turn, can lead to overactivation of SPS1-related proline/alanine-rich kinase or oxidative stress-responsive kinase and the NCC/ NKCC2 ion cotransporters, and consequently, increased salt retention and hypertension 51, 55, 56 ( Figure 2 ). Liddle syndrome (OMIM 177200) is an autosomal dominant condition with a clinical picture of hypertension and aldosterone excess, but with low aldosterone and renin levels, caused by mutations in the genes coding the β or γ subunits of ENaC (SCNN1B, SCNN1G), resulting in deletions of proline-rich regions. 57, 58 These regions facilitate binding of Nedd4-2 (NEDD4L), a regulatory repressor that promotes channel degradation. The inability of β and γ subunits to bind Nedd4 results in constitutive expression of sodium channels and prolongation of the half-life of ENaCs at the renal distal tubule apical cell surface, leading to increased rates of sodium reabsorption, volume expansion, and hypertension. Treatment of Liddle syndrome with amiloride or triamterene lowers BP and corrects the hypokalemia and acidosis. These agents effectively block the constitutively active ENaC in the collecting tubule. Specific aldosterone antagonists, such as spironolactone and epleronone, play no role in the treatment of this condition because the increased activity of the ENaC is not mediated by aldosterone.
Mutations that reduce salt retention, such as those associated with Bartter (SLC12A1, KCNJ1, CLCNKB, BSND, CaSR, and ClCK-A) and Gitelman (SLC12A3) syndromes, tend to lower BP and protect against the development of hypertension. 11, 59 Resequencing 3 target genes (SLC12A3, SLC12A1, and KCNJ1) involved in Bartter and Gitelman syndrome in the Framingham Heart Study population identified 30 distinct potentially deleterious rare mutations present in 49 subjects. In the heterozygous state, these variants were associated with 5.7 mm Hg lower BP at the age of 40 years and with 9.0 mm Hg at the age of 60 years and in aggregate reduces the risk of hypertension by 60% at the age of 60 years. 59 This is the first indication that rare variants can produce clinically significant BP reduction in the general population and support the rarevariant-common-disease hypothesis.
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Primary Aldosteronism
Aldosterone regulates plasma volume through its modulation of Na + and Cl -absorption in the colon and kidney, and thus is an important mediator of hypertension. Aldosterone is secreted by the adrenal glomerulosa cells that are normally hyperpolarized because of a predominant K + conductance mediated by channels of the K2P family, TASK1 (KCNK3), TASK3 (KCNK9), and TREK1 (KCNK2). 62, 63 Signaling through the angiotensin II type 1 receptor inhibits these potassium currents, resulting in glomerulosa membrane depolarization and activates low-voltage-activated (T-type) calcium channels, leading to calcium influx, activation of the calcium/ calmodulin kinase pathway leading to increased production of rate-limiting enzymes for aldosterone biosynthesis and increased aldosterone production. 64 Another cause of glomerulosa membrane depolarization is hyperkalemia. Constitutive Figure 2 . Molecular pathways affecting sodium transport involving Cullin 3 (CUL3), Kelch-like 3 (KLHL3), and Uromodulin (UMOD). Cul3 E3 ligase complex can regulate WNK4 function. The Cul3 ubiquitin ligase activity is promoted by its binding to Nedd8, and Cul3 can interact with KLHL3 and ubiquitylates WNK4. The regulation of Cul3 neddylation and Cul3 activity could be considered as a new form of modulation of WNK4 pathway in distal convoluted tubular and collecting duct cells. Mutations in Cul3 or KLHL3 can lead to hypertension by impaired interaction with and ubiquitination of WNK4 and is proposed that any deregulation in its function could lead to hypertension. Molecular context of UMOD in the thick ascending limb of loop of Henle cells. UAKD mutations are restricted to exons 3 and 4. Genome-wide association study (GWAS) single nucleotide polymorphisms (SNPs) for hypertension and chronic kidney disease are located in the promoter end of the gene and variants with reduced UMOD expression can result in a shift to the left of the pressurenatriuresis curve. The region of linkage disequilibrium (LD) around the GWAS SNP is longer for Europeans, but much smaller among those of African and East Asian ancestries. The mechanism of UMOD effect on glomerular filtration rate is not clear and likely involves tubuloglomerular feedback. CEU, European ancestry; CD, collecting duct; ClC-Ka, chloride channel protein class Ka; Clc-Kb, chloride channel protein class Kb; DCT, distal convoluted tubule; E.R., endoplasmic reticulum; GPI, glycosylphosphatidylinositol; JPT, Japanese ancestry; MD, macula densa; NKCC2, Na+ K+ 2Cl− cotransporter 2; PCT, proximal convoluted tubule; ROMK, renal outer medullary potassium channel; TAL, thick ascending limb of loop of Henle; UAKD, uromodulin associated kidney disease; and YRI, African ancestry (Illustration credit: Ben Smith). by guest on http://circres.ahajournals.org/ Downloaded from aldosterone secretion in the absence of angiotensin II or hyperkalemia causes primary aldosteronism, which is present in ≈2% of the general population, 10% of hypertension in referral centers, and possibly 20% to 25% of resistant hypertension. 12, 65 Primary aldosteronism most commonly results from bilateral adrenal hyperplasia and other less common causes include unilateral adrenal hyperplasia, APA, and ≈5% of individuals have Mendelian forms of primary aldosteronism. 66, 67 Individuals with primary aldosteronism constitutively produce aldosterone from the adrenal gland, resulting in hypertension with variable hypokalemia and a suppressed circulating renin. The distinction between APA and bilateral hyperplasia is clinically important because removal of the affected adrenal gland in APAs cures or ameliorates hypertension in the majority of patients, whereas bilateral adrenal hyperplasia requires lifelong treatment with an aldosterone antagonist and bilateral adrenalectomy is not indicated. Following a landmark exome sequencing study 68 and subsequent independent replication studies, it is estimated that ≤40% of APAs harbor a gain-offunction somatic mutation in a K + channel, KCNJ5, which results in membrane depolarization and enhanced aldosterone production.
63 KCNJ5 encodes the G-protein-activated inward rectifier K + channel 4, GIRK4 (also called the inward rectifier K + channel, Kir3.4). Mutations in 3 other genes have been discovered in a further 7% of APAs-ATP1A1, encoding the α1 subunit of Na + /K + -ATPase itself; and ATP2B3, encoding a plasma membrane Ca 
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The gain of function KCNJ5 mutations in APAs result in amino acid substitutions, Gly151Arg and Leu168Arg predominantly and more rarely Glu145Gln, Thr158Ala, and Ile157del. 63 These residues are situated in or around the selectivity filter of the K + channel pore (which is conserved among all K + channels in the biological world) and in several cases have been shown to cause a loss of channel selectivity resulting in sodium entry and membrane depolarization and the opening of voltage-gated Ca 2+ channels. 63 Expression studies show that the mutant channels have increased Na + conductance sufficiently large to cause marked cellular depolarization. The ATP1A1 mutations mainly involve the L104 residue, whereas ATP2B3 involve 3 different in-frame DNA deletions. [69] [70] [71] In vitro studies have shown that ATPA1 mutations have a profound effect on K + binding and ATPase activity and cause membrane depolarization leading to the opening of voltage-dependent Ca 2+ -channels. 70 Ca V 1.3 is a molecular target of the L-type Ca 2+ channel blockers, and electrophysiological studies of mutant CaV1.3 channels implicate increased Ca 2+ influx in disease pathogenesis. 71 Interestingly, a substantial proportion of APAs resembling adrenal zona glomerulosa cells harbor gain-of-function mutations in genes important for the regulation of Na + and Ca
2+
, ATP1A1 and CACNA1D, respectively, whereas KCNJ5 mutations are common in APAs resembling cortisol-secreting cells of the adrenal zona fasciculata. 65, 69 
Glucocorticoid Pathway
Defects in enzymes of cortisol biosynthesis result in a group of autosomal recessive disorders collectively called congenital adrenal hyperplasia. 72 In some of these syndromes, plasma ACTH will increase in an attempt to produce cortisol, and the some of the aberrant products that accumulate can result in hypertension. Enzyme mutations that are associated with hypertension include (in order of frequency) 11β-hydroxylase (OMIM 202010; CYP11B1), 3β-hydroxysteroid dehydrogenase (OMIM 613890; HSD3B2), 17α-hydroxylase (OMIM 609300; CYP17A1), and cholesterol desmolase (OMIM 118485; CYP11A1). 11β-Hydroxylase deficiency is caused by several mutations in the CYP11B1 gene. The recessively inherited enzymatic defect results in elevated serum levels of deoxycorticosterone, the principal steroid index of 11β-hydroxylase deficiency. This responds to glucocorticoid therapy and normalization of deoxycorticosterone is an indicator of adequate therapy. Hydrocortisone is frequently used in children to maximize their growth potential while minimizing their risk for developing iatrogenic Cushing syndrome. In selected patients, bilateral adrenalectomy may be safe and effective in managing BP. In such cases, mineralocorticoid replacement is always necessary unless a high salt intake is consumed. Cortisol therapy is also the mainstay of therapy for 17α-hydroxylase deficiency.
Sympathetic Pathway
Phaeochromocytomas and paragangliomas are rare neuroendocrine tumors of the adrenal glands and the sympathetic and parasympathetic paraganglia. The annual incidence of phaeochromocytoma is ≈2 to 4 per million. Phaeochromocytomas and sympathetic paragangliomas are similar histologically, as well as functionally, and cause hypertension, which may be either paroxysmal or sustained. About 30% of phaeochromocytomas and paragangliomas are currently thought to be caused by germline mutations. Autosomal dominantly inherited phaeochromocytomas are because of a variety of RET pro-to-oncogene mutations. Other pheochromocytomasusceptibility genes include the tumor suppressor gene VHL observed in families with von Hippel-Lindau syndrome, and the gene that encodes succinate dehydrogenase subunits A, B, C, and D (SDHA, SDHB, SDHC, and SDHD, respectively) with heterozygous germline mutations of SDHB, SDHC, and SDHD causing the well-characterized familial pheochromocytoma-paraganglioma syndromes known, respectively, as paraganglioma 4, paraganglioma 3, and paraganglioma 1 73 . Newer predisposing genes for phaeochromocytoma/paraganglioma include KIF1Bbeta, PHD2, and SDHAF2. 74 Phaeochromocytoma or paraganglioma are frequent (28.2%), but inheritance is evident at presentation only in 16.9% of cases. Germline mutations have been reported in 7% to 24% of apparently sporadic cases. Despite increased costs, systematic targeted genetic screening of RET, SDHB, SDHC, SDHD, and VHL might be useful because it might lead to a stricter followup, early diagnosis of recurrences in index cases and presymptomatic detection of disease in relatives, and predicting tumor predisposition that has clinical advantages. 75 Treatment is with α-blockers followed by β-blockers and surgical resection.
Exome Sequencing
The success of exome sequencing in identifying mutations for pseudohypoaldosteronism II has to date not been realized by guest on http://circres.ahajournals.org/ Downloaded from for polygenic BP trait. Albrechtsen et al 76 analyzed a Danish population by performing whole exome sequencing in 1000 cases (with type 2 diabetes mellitus, body mass index >27.5 kg/m 2 and hypertension) and 1000 controls, followed-up by SNP genotyping in a further 15 989 Danes. Results were then replicated for 45 SNPs in 63 896 Europeans. No SNPs were found to be associated with hypertension, systolic BP, or diastolic BP in this study. The identification of low-frequency variants will require substantially larger sample sizes than that used for GWAS and there are large collaborative efforts ongoing currently in this area.
Common Variants and Novel Pathways
There is emerging evidence of a novel pathway, mediated by the Uromodulin (UMOD) gene (which is exclusively expressed in the thick ascending limb of the loop of Henle in the kidney), which influences BP with the potential to improve hypertension management and new drug development. 30, 32, 77 In a GWAS of BP extremes, the minor G allele of a UMOD promoter SNP, rs13333226, was associated with a lower risk of hypertension (odds ratio [95% confidence interval], 0.87 [0.84-0.91]) and reduced urinary UMOD excretion. 22 Mechanistic studies in mouse models showed that UMOD knockout mice had significantly lower systolic BP than wildtype mice, were resistant to salt-induced changes of BP, and demonstrated a leftward shift of the pressure-natriuresis curve. 30 These findings were further independently extended by Trudu et al 32 who in a complementary set of experiments showed that UMOD overexpression caused a dose-dependent increase in UMOD expression and excretion, associated with an increase in BP. They also showed that loop diuretic (furosemide) treatment significantly enhanced natriuresis and reduced BP levels both in the transgenic mice and in the hypertensive individuals homozygous for the UMOD increasing allele (Figure 2 ). These studies raise the possibility that hypertensive patients who possess the UMOD-increasing allele will respond better to blockers of NKCC2 (loop diuretics). Because volume overload is considered as one of the primary underlying reasons for resistant HTN, targeting loop diuretics to individuals who are more likely to respond to this drug would be a more efficient strategy compared with an all-comers approach to combat resistant hypertension.
Evidence from population genetic studies suggests that variation in the plasma levels of natriuretic peptides may alter susceptibility to cardiovascular disease via effects on BP. Within the heart, the brain natriuretic peptide (BNP) gene (NPPB) produces a 134 amino acid prepro-BNP precursor peptide, which after removal of a 26 amino acid signal peptide results in the 108 amino acid prohormone-pro-BNP. 78 Subsequently, the enzyme corin cleaves pro-BNP into the biologically active mature 32 amino acid BNP (BNP 1-32) containing the critical 17 amino acid disulfide ring. A second cleavage product is the linear 76 amino acid N-terminal peptide (NT)-pro-BNP 1 to 76. The mature BNP 1 to 32 binds to the natriuretic NRP-A receptor, activates the production of the second messenger cGMP, and mediates the biological actions of BNP. These actions include natriuresis, vasodilatation, enhancement of ventricular relaxation, inhibition of fibroblast activation, and suppression of the renin-angiotensin-aldosterone system. These peptides are degraded approximately equally by 2 mechanisms, enzymatic degradation catalyzed by membrane metalloendopeptidase and clearance by natriuretic peptide receptor-3 (NPR3). 79 All 3 natriuretic peptides, atrial natriuretic peptide (ANP), BNP, and C-type natriuretic peptide, seem to have similar binding affinity for NPR3, and genetic variation in NPR3 has been associated with variation in BP regulation among both Europeans and East Asians. 20, 21 Common SNPs in the chromosomal region containing NPPA and NPPB, the genes encoding the ANP and BNP propeptides, are associated with circulating levels of the natriuretic peptides. 18 Large-scale epidemiological studies have established that the same variants are associated with BP. 18, 21 The SNP that is associated with plasma ANP levels most strongly is rs5068 (A/G): carriers of the rs5068 minor G allele have a 15% lower risk of hypertension than do those with 2 copies of the major A allele. The rs5068 SNP is located in the 3′ untranslated region of the NPPA gene. It has recently been recognized that small noncoding RNAs called microRNAs (miRNAs) play a role in posttranscriptional regulation of gene expression by binding to 3′ untranslated regions. 80 Binding of miRNAs to mRNAs typically requires complementarity of a seed sequence at positions 2 to 7 of the 5′ end of the miRNA. 81 Recently, a microRNA (miR-425) was identified, that is expressed in human atria and ventricles and is predicted to bind the sequence spanning rs5068 for the A, but not the G, allele. 33 miR-425 silenced NPPA mRNA in an allele-specific manner, with the G allele conferring resistance to miR-425, suggesting that miR-425 is a regulator of ANP production, raising the possibility that miR-425 antagonists could be used to treat disorders of salt overload, including hypertension and heart failure. 33 The genetic effect of rs5068 on circulating NT-pro-ANP levels is comparable with the environmental change induced by switching from an extremely low-salt diet (230 mg/d) to a diet with salt content typical of a Western diet (4600 mg/d).
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Salt Sensitivity
Among the environmental factors that affect BP, dietary sodium chloride has been studied the most and there is general consensus that increased sodium chloride intake increases BP. The role for NaCl is hypertension is supported by insights from the pressure-natriuresis mechanism, monogenic forms of hypertension, and dietary salt intervention studies. 82, 83 Salt sensitivity is a quantitative trait in which an increase in sodium load leads to an increase in BP. 84 Overall, salt sensitivity has been estimated to be present in 51% of hypertensive and 26% of normotensive subjects and is a major public health problem. 85 Candidate gene association studies have shown varying degrees of association with salt sensitivity, including ATP2B1, STK39, and GRK4, genes of the renin angiotensin system with the best evidence to date related to the sodiumbicarbonate cotransporter gene (SLC4A5).
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Missing Heritability in GWAS
Despite the discovery of multiple validated SNPs for BP, the striking finding is that the associated variants are all of small effect and the cumulative proportion of heritability explained if small, and this holds true for all other complex traits subjected to GWAS. 21, 87 However, this is probably not a catastrophic issue if the caveats of heritability estimation are recognized. The heritability of BP from family studies varies from 30% to 50%, [6] [7] [8] [9] [10] but the collective effect of all BP loci identified through GWAS explains ≈2% of BP heritability. 21 Heritability reflects the degree of phenotypic resemblance between relatives and this not only depends on shared genetic factors contributing to the trait but also includes environmental factors and interactions within the genome. The proportion of heritability explained by a set of variants is the ratio of the heritability caused by these variants, estimated directly from their observed effects, to the total heritability inferred indirectly from population data. 88 Heritability estimates can increase or decrease without any genetic changes, for example, when environmental variation decreases or increases, respectively. The observed BP heritability of BP does not reflect the true magnitude of genetic effect, but instead reflects the amount of variation in genotypic effects compared with variation in environmental effects. Environmental conditions vary between populations and indeed between generations and hence heritability estimates only refer to specific populations under a specific environment. So overestimation of the population heritability leads to phantom heritability that can dilute the proportion of heritability explained. Using a linear mixed-effects model to estimate heritability caused by genetic variants that are not significantly associated with the phenotype, the heritability of Crohn disease was estimated at 22% than at 50% to 60% from family studies. 89 Another factor that influences heritability estimates is a measurement error. This is clearly illustrated above where minimizing measurement errors using ambulatory night-time values or using long-term average BP results in higher heritability estimates. Other reasons for the missing heritability include the presence of other additional causal variation is present at the known GWAS loci but not fully quantified by individual GWAS markers and the presence of additional undiscovered variants with smaller effect sizes that have not been detected with stringent significance. 90 It is more likely that missing heritability need not directly correspond to missing variants because current estimates of total heritability may be significantly inflated by genetic interactions.
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Future
Understanding the genetic architecture of BP and hypertension has been boosted by technological innovations in high-throughput genotyping and sequencing and large-scale international collaborative efforts. However, although studies of monogenic syndromes have rapidly exposed causative molecular pathways perturbing BP regulation, there has been only limited functional linkage of GWAS signals to molecular pathways. Thus, the major challenge for the near term is to transform the SNP discoveries from GWAS to causal molecular mechanisms. At this juncture, where discovery of genetic variants associated with the BP trait is progressing in a stepwise manner with increasing sample sizes along with the use of imputation and bioinformatic tools, it is instructive to look at the history of BP genetics research and predict the future. Figure 3 shows the complete historical context of hypertension and BP genetics, and it is striking that 21st century genomic technologies are used to dissect the BP phenotype which is measured by methods defined over a century ago. Certainly in current clinical practice, BP is a convenient measure with enormous clinical value supported by decades of clinical trials and prospective research but perhaps this is not an accurate or granular measure of the underlying perturbed physiological pathways and hence the difficulty in the genetic dissection of the polygenic trait. Newer phenotypic parameters that can accurately reflect underlying perturbed mechanisms or subphenotypes are essential for advancing discovery through genetic dissection. Measurements of pulse wave velocity, central BP, are phenotypic measures that are thought to be better markers of risk, but progress is slow and limited in the uptake of these on a large scale. Interestingly from Figure 3 , we note that the discovery and development of antihypertensive drugs occurred independently and predated most of the BP gene discoveries. Some of the monogenic genes turned out to be targets of antihypertensive drugs and linking the genes to pharmacotherapy occurred in a post hoc manner. Moreover, the therapeutic panel in Figure 3 reflects the limited number of pathways targeted by current drugs, and the paucity of novel pathways can stimulate new drug development. It is in this space that GWAS and the current discovery studies can play a significant role in drug discovery. Recent GWAS studies have focused on extensive in silico bioinformatic approaches to relate GWAS SNPs to drug targets. However, the potential of GWAS can only be realized if the SNPs can be linked to causal genes and pathways, which can then be targeted for therapeutic interventions. The discovery of UMOD is an example of a new pathway uncovered by GWAS that can potentially be a drug target; however, this also highlights the scale of physiological and molecular dissection, drug discovery, and development that is required. To maximize successful clinical translation, the panel of >50 SNPs that have been discovered for BP needs to be functionally dissection and this requires the same scale of collaborative efforts that led to their discovery in the first place, to ensure that clinical benefit can be achieved soon.
